ONCY News and Press, Oncolytics Biotech Inc. From 10/14/21

Compared to the Dow Jones Industrial Average which has gained an impressive 10.6% through Q3 2021, and the S&P 500 and Nasdaq doing even better with 14.7% and 12.1% gains respectively, the biotech sector has been lagging behind . The Nasdaq Healthcare Index has only gained 4.2%, whi...

VANCOUVER – USA News Group – Oncology data leader COTA recently released a recent survey where half of the respondents pointed to “Operation Warp Speed” as evidence that cancer treatments can and should be moving forward fast...

Palm Beach, FL – October 14, 2021 – FinancialNewsMedia.com News Commentary – The breast cancer drugs market, which has been steadily growing over the past few years, is projected to continue this trend for the next several years. The breast cancer drugs mark...

Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer PR Newswire Trial is designed to advance pelareorep's clinical development in China , the world's seco...

FN Media Group Presents USA News Group News Commentary Vancouver, BC –September 20, 2021 – USA News Group –  Oncology data leader COTA recently released a recent survey where half of the respondents pointed to “Operation Warp Spee...

Palm Beach, FL – September 20, 2021 – FinancialNewsMedia.com News Commentary – Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective, low-cos...

Oncolytics Biotech® Announces Preclinical Data Demonstrating the Synergistic Immunotherapeutic Effects of Pelareorep Combined with Radiotherapy Combination treatment with pelareorep and radiotherapy promoted the tumor infiltration of anti-cancer T cells and prolonged surviv...

Oncolytics Biotech Inc. (ONCY) Q2 2021 Results Earnings Conference Call August 06, 2021, 08:00 AM ET Company Participants Jon Patton - Director, IR and Communication Matt Coffey - President and CEO Tom Heineman - Global Head, Clinical Development and Operations Andrew de Guttadauro - Global H...

Oncolytics Biotech (NASDAQ:ONCY): Q2 GAAP EPS of -$0.13 misses by $0.03. Cash and cash equivalents of $50.8M Press Release For further details see: Oncolytics Biotech EPS misses by $0.03

Oncolytics Biotech® Reports 2021 Second Quarter Development Highlights and Financial Results Canada NewsWire - Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: ...